91 New research has revealed that angiosarcoma, a rare and aggressive cancer of the blood vessels, may be more prevalent in Japan than earlier estimates suggested, particularly among older men. The study, which analysed national cancer registry data from 2016 to 2019, offers the most comprehensive insight yet into the demographics, treatment patterns, and survival outcomes of patients with this little-understood form of sarcoma. The findings were published in the journal Scientific Reports. Angiosarcoma accounted for 8.4% of all soft-tissue sarcomas identified during the four-year period, translating to an age-adjusted incidence of 0.18 per 100,000 people annually. This is lower than the rates reported in Western countries, such as the United States and France, but still significant given the disease’s aggressive nature and poor prognosis. The majority of cases were diagnosed in men, with 58.7% of patients being male. Notably, over half of the tumours occurred in the head and neck region, and most diagnoses were made in people aged 75 and older. The findings also revealed a stark difference in survival rates between angiosarcoma and other types of soft-tissue sarcoma. Just over one in four patients with angiosarcoma survived beyond three years, compared to more than two-thirds of those with non-angiosarcoma sarcomas. Survival was especially poor in patients with tumours that had spread beyond the original site, those whose cancers originated in internal organs, and those who did not receive surgery or other treatments. Patients were more likely to undergo chemotherapy or radiotherapy than surgery, a trend that diverges from treatment approaches typically seen in Western nations. In Japan, only 32.3% of angiosarcoma patients received surgery, compared to over half in comparable American studies. This may partially explain the country’s lower survival rates, as surgery was found to significantly improve overall outcomes. There were also considerable differences based on tumour location. Angiosarcomas in the breast had the best prognosis, while those in the visceral organs and unspecified locations fared the worst. Interestingly, angiosarcoma of the breast tended to affect younger women, whereas head and neck tumours were far more common in elderly men. These distinctions suggest that different biological or environmental factors may be at play depending on the tumour’s origin. The study is the first of its kind in Japan to use population-wide data to assess the national burden of angiosarcoma. By drawing from the National Cancer Registry, which compiles legally mandated reports from hospitals across the country, researchers were able to analyse nearly 2,000 cases. This marked a substantial improvement over previous efforts, which relied on more limited datasets that often underrepresented patients outside specialist centres. Despite its limitations, including a lack of data on tumour size and treatment specifics, the study provides an important foundation for improving clinical strategies. Researchers believe the registry will become increasingly valuable in identifying trends and informing treatment guidelines, especially as more data are added in future years. Angiosarcoma remains one of the most challenging cancers to treat, and outcomes are still poor across the board. However, understanding its demographic patterns and treatment responses more clearly could open the door to better outcomes for patients facing this aggressive disease.